Looking Towards the Future: Moving Targeted Therapies for mEC Into the First-Line Setting
October 25th 2022
Experts discuss ongoing clinical trials focused on moving second-line and higher targeted therapies, including immunotherapy, into the frontline setting for mEC, and then comment on how these advances might impact treatment paradigms and patient outcomes.